Table 1.
Scoring and categorization of cognitive dysfunction*.
Table 2.
Clinical and laboratory features of SLE patients (N = 43) enrolled in the study.
Table 3.
Treatments at baseline (T0) and after 10 years (T1) of 43 SLE patients.
Table 4.
Disease activity and chronic damage at baseline (T0) and after 10 years (T1) in 43 SLE patients.
Fig 1.
Distribution of neurocognitive impairment, expressed as MDZ scores ±SD, in the patients enrolled at baseline (T0) and after 10 years.
Fig 2.
Percentage of patients with neurocognitive impairment, expressed as DCDs, in all the domains evaluated at T0 and T1.
Absent: DCD = 0; Mild: DCD = 1; Moderate: DCD = 2.